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Objectives This study sought to compare the safety and efficacy of 2 dose formulations of SYNERGY, a novel bioabsorbable
polymer everolimus-eluting stent (EES) (Boston Scientific Corp., Natick, Massachusetts) compared with the dura-
ble polymer PROMUS Element EES (Boston Scientific Corp.).
Background Durable polymer coatings on drug-eluting stents have been associated with chronic inflammation and impaired
healing. Bioabsorbable polymer-coated drug-delivery systems may reduce the risk of late adverse events, includ-
ing stent thrombosis, and thus the need for prolonged dual-antiplatelet therapy.
Methods A total of 291 patients with a de novo lesion 28 mm in length, in a coronary artery of 2.25 to 3.5 mm di-
ameter, were enrolled in the EVOLVE study, a prospective, randomized, single-blind, noninferiority trial. Patients
were randomly assigned in a 1:1:1 ratio to PROMUS Element, SYNERGY, or SYNERGY half dose. The primary clini-
cal endpoint was the 30-day rate of target lesion failure, defined as cardiac death or myocardial infarction related to
the target vessel, or target lesion revascularization. The primary angiographic endpoint was 6-month in-stent late loss
measured by quantitative coronary angiography.
Results The 30-day primary clinical endpoint of target lesion failure occurred in 0%, 1.1%, and 3.1% of patients in the
PROMUS Element, SYNERGY, and SYNERGY half dose groups, respectively. The 6-month in-stent late loss was
0.15  0.34 mm for PROMUS Element, 0.10  0.25 mm for SYNERGY, and 0.13  0.26 mm for SYNERGY half
dose (SYNERGY, difference 0.06, upper 95.2% confidence limit: 0.02, p for noninferiority 0.001; SYNERGY
half dose, difference 0.03, upper 95.2% confidence limit: 0.05, p for noninferiority 0.001). Clinical event
rates remained low and comparable between groups, with no stent thromboses in any group at 6 months.
Conclusions The EVOLVE trial confirms the effective delivery of everolimus by a unique directional bioabsorbable polymer
system utilizing the SYNERGY stent. (A Prospective Randomized Multicenter Single-Blind Noninferiority Trial to
Assess the Safety and Performance of the Evolution Everolimus-Eluting Monorail Coronary Stent System [Evolu-
tion Stent System] for the Treatment of a De Novo Atherosclerotic Lesion [EVOLVE]; NCT01135225) (J Am Coll
Cardiol 2012;59:1362–70) © 2012 by the American College of Cardiology Foundation
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April 10, 2012:1362–70 Primary Endpoint Results of the EVOLVE TrialDrug-eluting stents delivering antiproliferative drugs from a
durable polymer have significantly reduced angiographic and
clinical measures of restenosis compared with bare-metal
stents, with no apparent increase in the risk of adverse events
including death and myocardial infarction (MI) (1–4). How-
ever, durable polymers have been associated with a hypersen-
sitivity reaction, delayed healing, and incomplete endothelial-
ization that may contribute to an increased risk of late (30 days
to 1 year) and very late (beyond 1 year) stent thrombosis
compared with bare-metal stents (5–7). Although the ability of
prolonged dual-antiplatelet therapy (DAPT) with aspirin and
a thienopyridine to prevent late thrombotic events is as yet
unproven, current clinical practice guidelines in the United
States and Europe recommend at least 12 months of DAPT
after treatment with drug-eluting stents (8,9). Prolonged
DAPT raises several potential concerns including the risk of
bleeding, patient compliance, implications of DAPT interrup-
tion for invasive procedures, and the economic costs of pro-
longed drug treatment. A number of stent technologies are
being developed in an attempt to modify the proposed medi-
ators of late thrombotic events and the need for prolonged
DAPT, including bioabsorbable polymers, nonpolymeric stent
surfaces, and bioabsorbable stents. The SYNERGY stent (Boston
Scientific Corp., Natick, Massachusetts) is a novel device consist-
ing of a thin-strut platinum-chromium stent platform that delivers
everolimus from an ultrathin bioabsorbable poly(DL-lactide-co-
glycolide) (PLGA) polymer applied to the abluminal surface.
Endothelialization is complete within 28 days of implantation
in a porcine coronary artery model (10), and polymer reabsorp-
tion is complete within 4 months (11).
In the randomized, first-human-use EVOLVE (A Prospec-
tive Randomized Multicenter Single-Blind Non-inferiority
Trial to Assess the Safety and Performance of the Evolution
Everolimus-Eluting Monorail Coronary Stent System [Evo-
lution Stent System] for the Treatment of a De Novo Ath-
erosclerotic Lesion) trial (Evolusion has been renamed to
SYNERGY), we compared the safety and efficacy of 2 dose
formulations of the SYNERGY stent with those of the durable
polymer PROMUS Element everolimus-eluting stent (EES)
(Boston Scientific Corp.), which has demonstrated an excellent
safety and efficacy profile and has been shown to be noninferior
to predicate cobalt-chromium EES for target lesion failure
(TLF) at 12 months (12,13). The safety and efficacy of lower
doses of everolimus have not been adequately studied. In the
EVOLVE trial, we evaluated 1 formulation of the SYNERGY
stent with a total everolimus dose similar to that of the
currently available EES and a second formulation with half the
dose of everolimus to determine if comparable efficacy could be
achieved with a lower, and therefore potentially safer, drug
dose. In this report, we present the primary endpoint results of
the EVOLVE trial.
Methods
Study design and patients. The EVOLVE study is a
prospective, randomized, multicenter, single-blind, nonin-feriority trial conducted at 29
sites in Europe, Australia, and
New Zealand. From July 29,
2010, to January 20, 2011, 291
patients 18 years of age and older
with symptomatic coronary ar-
tery disease or silent ischemia
were recruited. Patients were el-
igible for inclusion if they had a
de novo lesion that was 28 mm
in length in a native coronary
vessel with a reference diameter
of 2.25 mm to 3.5 mm. Addi-
tional key eligibility criteria were
stenosis 50% and absence of
coronary occlusion (Thromboly-
sis In Myocardial Infarction
[TIMI] flow grade 1). Major
exclusion criteria were acute or
recent MI, lesions located in the
left main coronary artery, rest-
enotic lesions, lesions involving a side branch 2 mm in
diameter, or the presence of thrombus in the target vessel.
All eligible patients provided written informed consent. The
study complied with the Declaration of Helsinki, and the
protocol was approved by the ethics committee at all
participating sites. An independent clinical events commit-
tee adjudicated all deaths, stent thromboses, target vessel
revascularizations (TVRs), and MIs, and an independent
data monitoring committee monitored patient safety.
Study devices. The SYNERGY stent consists of a thin-
strut, balloon-expandable platinum-chromium stent plat-
form delivering everolimus from an ultrathin (4 m) bio-
absorbable PLGA polymer applied to the abluminal surface.
One formulation (SYNERGY) has a similar dose (38 g to
179 g, depending on stent length) and release profile as
PROMUS Element, whereas the second formulation
(SYNERGY half dose) has a similar release profile but half
the dose of everolimus (19 g to 90 g, depending on stent
length) as PROMUS Element (14). The durable polymer
platinum-chromium PROMUS Element stent, which
served as a control in this study, has been described
previously (12,13).
Randomization and blinding. The randomization sched-
ule was computer generated and stratified by study site and
the presence or absence of medically treated diabetes mel-
litus. Patients were assigned in a 1:1:1 ratio to PROMUS
Element, SYNERGY, or SYNERGY half dose. Study
investigators were not blinded to treatment assignment;
however, the patients and members of the independent
clinical events committee, data monitoring committee, core
laboratory, and the sponsor were blinded.
Procedures. Study stents were available in diameters ranging
from 2.25 mm to 3.5 mm and lengths of 8 mm, 20 mm, and
Abbreviations
and Acronyms
CK-MB  creatine kinase-
myocardial band
DAPT  dual-antiplatelet
therapy
EES  everolimus-eluting
stent(s)
MI  myocardial infarction
PLGA 
poly(DL-lactide-co-glycolide)
QCA  quantitative
coronary angiography
TLF  target lesion failure
TLR  target lesion
revascularization
TVF  target vessel failure
TVR  target vessel
revascularization32 mm. Percutaneous coronary intervention was performed
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Primary Endpoint Results of the EVOLVE Trial April 10, 2012:1362–70using standard techniques. The aim was to obtain full lesion
coverage with 1 stent. Treatment of 1 nontarget lesion in a
nontarget vessel with a commercial treatment (excluding
brachytherapy) was allowed if it occurred before target lesion
intervention and was deemed a clinical and angiographic
success (defined as visually assessed mean lesion diameter
stenosis 50% [30% for stents] with TIMI flow grade 3,
ithout prolonged chest pain or MI). Planned revasculariza-
ions after the index procedure were prohibited.
Procedural anticoagulation was achieved with unfraction-
ted heparin or an alternative antithrombotic such as enoxa-
arin or bivalirudin. Glycoprotein IIb/IIIa inhibitor use was
ermitted per investigator discretion. Loading doses of aspirin
nd clopidogrel (300 mg) were required for patients not
aking these medications 72 h before the index procedure.
atients continued to take aspirin (at least 75 mg daily)
ndefinitely. Clopidogrel (75 mg daily) was required for at least
months after stent placement in all patients, and for at least
2 months in those not at high risk of bleeding. Prasugrel was
ermitted in accordance with approved country-specific label-
ng. Clinical follow-up was scheduled for 30 days, 6 months, 9
onths, and annually from 1 to 5 years. Quantitative coronary
ngiography (QCA) follow-up was scheduled for 6 months
ost-procedure.
tudy endpoints. The primary clinical endpoint was TLF,
composite of cardiac death or MI related to the target
essel, or ischemia-driven target lesion revascularization
TLR) at 30 days. Cardiac death was defined as any death
ther than those confirmed to have a noncardiac cause.
yocardial infarction was defined as either the development
f new pathological Q waves in2 leads (duration0.04 s)
ith elevated levels of creatine kinase-myocardial band
CK-MB) or troponin; or, in the absence of new Q waves,
levation of CK 3 times normal (periprocedural MI,
ccurring within 48 h of the procedure) or2 times normal
spontaneous MI) with elevated CK-MB, or troponin 3
imes normal (periprocedural MI) or 2 times normal
spontaneous MI), plus any 1 of the following: 1) electro-
ardiographic changes indicative of new ischemia (new
T-T changes or left bundle branch block); 2) imaging
vidence of new loss of viable myocardium; or 3) new
egional wall motion abnormality. Target lesion revascular-
zation and TVR were defined as revascularization of the
arget lesion and vessel with stenosis 50% by QCA,
espectively, if associated with clinical or functional isch-
mia (positive functional study, electrocardiographic
hanges, or ischemic symptoms), or stenosis 70% in the
bsence of clinical or functional ischemia.
The primary angiographic endpoint was in-stent late loss
s measured by an independent core laboratory QCA at 6
onths. Technical success was defined as successful delivery
nd deployment of the study stent to the target vessel,
ithout balloon rupture or stent embolization. Clinical
rocedural success was defined as visually assessed diameter
tenosis 30% in 2 near-orthogonal projections with TIMI
ow grade 3, without the occurrence of in-hospital MI, hVR, or cardiac death. Additional clinical endpoints in-
luded TLR, TVR, target vessel failure (TVF [defined as
eath related to the target vessel, MI related to the target
essel, or TVR]), cardiac death, noncardiac death, MI, and
tent thrombosis according to the definitions provided by
he Academic Research Consortium (15). Additional an-
iographic endpoints included in-segment late loss, percent
iameter stenosis, acute gain, rate of binary restenosis, and
inimal lumen diameter.
uantitative coronary angiography. Coronary angio-
rams recorded at baseline, post-procedure, and 6-month
ollow-up were analyzed by an independent angiographic
ore laboratory (Beth Israel Deaconess Medical Center,
oston, Massachusetts) using an automated edge detection
ystem (Medis Medical Imaging Systems, Leiden, the
etherlands). In each patient, QCA measures within the
tent and the analysis segment (including the stented region
nd 5 mm edge regions) were analyzed and reported separately.
ate loss was defined as the difference between the minimum
umen diameter post-procedure and at 6 months. Binary
estenosis was defined as 50% diameter stenosis.
tatistical analysis. This trial was powered for testing of
oninferiority for the 6-month primary angiographic end-
oint. Based on the data available from the SPIRIT III (A
linical Evaluation of the Xience V Everolimus Eluting
oronary Stent System) randomized trial, we anticipated
he 6-month in-stent late loss to be 0.14 mm in all groups
16). The criterion for noninferiority was considered to have
een met if the upper limit of the 1-sided 95.2% confidence
nterval for the difference between groups was not 0.20
m. An interim analysis was performed after 50% of
atients had been enrolled. The O’Brien-Fleming method
as used to adjust the alpha level for the final analysis,
here a p value 0.048 was required to reject the null
ypothesis and conclude noninferiority. No adjustments for
ultiple comparisons were made as each SYNERGY dose
as compared to the PROMUS Element control separately.
The study sample size was calculated for a 2-group (1:1
atio) test of equivalence in means using nQuery Advisor,
ersion 5 (Statistical Solutions, Saugus, Massachusetts). We
stimated that 97 patients per group would provide the study
ith a statistical power of 85% to detect noninferiority,
llowing for 20% patients lost to angiographic follow-up.
The testing of noninferiority was based on the per-
rotocol analysis cohort (only patients who received the
ssigned study stent). All other analyses were according to
he intention-to-treat principle. Categorical variables are
eported as numbers and percentages, and continuous vari-
bles as mean  SD. Differences between treatment groups
ith 95% confidence intervals and p values, on the basis of
he chi-square test or Fisher’s exact test for categorical
ariables and Student t test for continuous variables, are
eported. Analyses were performed with SAS, version 8.2 or
igher (SAS Institute, Cary, North Carolina).
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Figure 1 shows the patient flow. A total of 291 patients were
enrolled and randomly assigned to receive PROMUS Element
(n  98), SYNERGY (n  94), or SYNERGY half dose
n  99). Baseline clinical and angiographic characteris-
tics (Table 1) were similar in the 3 groups, except for a
larger reference vessel diameter in the SYNERGY half
dose group compared with the PROMUS Element group
(2.65  0.40 mm vs. 2.53  0.41 mm, p  0.04).
Technical success was achieved in 100%, 98.9%, and
98.0% patients and clinical procedural success was achieved
Figure 1 Patient Flow in the EVOLVE Trial
A total of 291 patients were enrolled and randomized in the EVOLVE trial, and 289
Baseline Clinical and Lesion CharacteristicsTable 1 Baseline Clinical and Lesion Characteristics
Characteristics
PROMUS Element
(n  98)
SYNERGY
(n  94)
Age, yrs 62.1 10.0 64.9 11.0
Men 79.6 69.9
Current smoker 27.8 21.7
Diabetes mellitus 22.4 17.2
Hyperlipidemia 70.4 68.5
Hypertension 69.4 61.3
Previous MI 34.4 32.3
Previous PCI 32.7 33.3
Previous CABG 1.0 2.2
Unstable angina 21.1 22.6
Target vessel
Left anterior descending 39.8 41.8
Left circumflex 31.6 26.4
Right coronary artery 28.6 31.9
RVD, mm 2.53 0.41 2.60 0.45
MLD, mm 0.68 0.30 0.68 0.30
Diameter stenosis 73.4 9.9 74.0 10.4
Lesion length, mm 14.62 5.81 13.41 6.29
AHA/ACC lesion classification B2/C 62.2 56.0
Values are mean  SD or %.
ACC  American College of Cardiology; AHA  American Heart Association; CABG  coronary artery
coronary intervention; RVD  reference vessel diameter.in 100%, 98.9%, and 97.0% patients in the PROMUS
Element, SYNERGY, and SYNERGY half dose groups,
respectively. One case of stent deformation was observed in
the PROMUS Element arm. During the post-implant
intravascular ultrasonography assessment, the catheter
caught on the proximal edge of the stent. The operator was
subsequently able to advance the intravascular ultrasound
catheter through the stent, but noted malapposition and
slight longitudinal compression afterward. Balloon angio-
plasty of the affected area was performed, with good result
and no clinical sequelae.
nts received the assigned study stent.
SYNERGY Half Dose
(n  99)
p Value
SYNERGY vs.
PROMUS Element
SYNERGY Half Dose vs.
PROMUS Element
62.9 10.2 0.07 0.61
69.7 0.12 0.11
20.6 0.33 0.24
18.2 0.36 0.46
72.4 0.77 0.75
71.7 0.24 0.72
34.7 0.76 0.96
38.4 0.92 0.40
3.1 0.62 0.62
30.6 0.80 0.13
39.4 0.78 0.95
33.3 0.43 0.80
27.3 0.62 0.84
2.65 0.40 0.22 0.04
0.67 0.31 0.96 0.94
74.7 10.5 0.69 0.35
13.55 5.76 0.16 0.21
69.7 0.39 0.27patiebypass graft; MI  myocardial infarction; MLD  minimal lumen diameter; PCI  percutaneous
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Primary Endpoint Results of the EVOLVE Trial April 10, 2012:1362–70Table 2 shows the clinical outcomes up to 6-month
ollow-up. The 30-day primary clinical endpoint of TLF
ccurred in 1.1% (n 1) in the SYNERGY group and 3.1%
n  3) in the SYNERGY half dose group compared with
o events in the PROMUS Element group. All 4 TLF
vents in the SYNERGY groups were attributable to target
essel–related periprocedural non–Q-wave MIs. At 6
onths, the TLF rate was 3.1%, 2.2%, and 4.1% in the
ROMUS Element, SYNERGY, and SYNERGY half
ose groups, respectively. The secondary endpoint of TLR
ccurred in 3.1%, 1.1%, and 1.0% patients in the PRO-
US Element, SYNERGY, and SYNERGY half dose
roups, respectively. There were no Q-wave MIs or
ardiac deaths in any group. One noncardiac death due to
motorcycle accident occurred in the SYNERGY group
t 191 days post-procedure. No stent thrombosis was
eported in any group (Table 2). At 6 months, 99.0%,
8.9%, and 94.8% patients were taking DAPT in the
ROMUS Element, SYNERGY, and SYNERGY half
ose groups, respectively.
The primary angiographic endpoint of in-stent late
oss was 0.15  0.34 mm for PROMUS Element, 0.10 
.25 mm for SYNERGY, and 0.13  0.26 mm for
YNERGY half dose. The upper 1-sided 95.2% confi-
ence limit of the difference between test and control was
.02 for SYNERGY and 0.05 for SYNERGY half dose,
oth lower than the pre-specified noninferiority margin
f 0.20 mm (p for noninferiority 0.001). Cumulative
requency distribution of in-stent late loss for the 3
roups is shown in Figure 2.
Clinical OutcomesTable 2 Clinical Outcomes
Clinical Outcomes
PROMUS Element
(n  98)
SYNERGY
(n  94)
Events at 30 days
Primary endpoint (TLF) 0.0 1.1
Cardiac death, related to TV 0.0 0.0
MI, related to TV 0.0 1.1
TLR 0.0 0.0
Events at 6 months
TLF 3.1 2.2
TVF 6.1 4.3
All deaths 0.0 1.1
Cardiac deaths 0.0 0.0
MI, overall 0.0 1.1
Q-wave MI 0.0 0.0
Non–Q-wave MI 0.0 1.1
TVR, overall 6.1 3.2
TLR, overall 3.1 1.1
Non-TLR TVR, overall 3.1 2.2
Stent thrombosis, ARC definition
Definite or probable 0.0 0.0
Values are %. *Not defined.
ARC Academic Research Consortium; MImyocardial infarction; TLF target lesion failure; TLR t
evascularization.Given that a small but statistically significant difference in
aseline reference vessel diameter was observed between the
YNERGY half dose group and the PROMUS Element
roup, we performed a post-hoc analysis of covariance to adjust
he primary angiographic endpoint of in-stent late loss for the
ifference in baseline reference vessel diameter. Adjusted
-month in-stent late loss was 0.15 mm for PROMUS
lement, 0.10 mm for SYNERGY, and 0.14 mm for
YNERGY half dose. The upper 1-sided 95.2% confidence
imit of the difference between test and control was 0.04
or SYNERGY and 0.08 for SYNERGY half dose.
imilar to the unadjusted in-stent late loss, both upper
-sided 95.2% confidence limits for the difference in
djusted late loss were lower than the pre-specified
oninferiority margin of 0.2 mm.
Table 3 shows QCA outcomes post-procedure and at 6
onths. Angiographic measurements were comparable
etween the PROMUS Element group and the SYN-
RGY group, whereas small but statistically significant
ifferences favoring SYNERGY half dose compared with
ROMUS Element were observed for a number of
ost-procedure parameters, including in-stent minimum
umen diameter (2.58  0.36 mm vs. 2.44  0.36 mm, p 
0.008), in-stent acute gain (1.90  0.38 mm vs. 1.76 
0.38 mm, p  0.01), and in-segment percent diameter
stenosis (17.08  6.90 vs. 19.57  9.26, p  0.04). At 6
months post-procedure, in-stent minimum lumen diam-
eter (2.45  0.44 mm vs. 2.29  0.50 mm, p  0.02),
and in-segment percent diameter stenosis (18.08  8.54
vs. 22.02  13.30, p  0.02) continued to favor SYN-
SYNERGY Half Dose
(n  99)
p Value
SYNERGY vs.
PROMUS Element
SYNERGY Half Dose vs.
PROMUS Element
3.1 0.49 0.25
0.0 * *
3.1 0.49 0.25
0.0 * *
4.1 1.00 0.72
5.2 0.75 0.77
0.0 0.49 *
0.0 * *
3.1 0.49 0.12
0.0 * *
3.1 0.49 0.12
2.1 0.50 0.28
1.0 0.62 0.62
1.0 1.00 0.62
0.0 * *arget lesion revascularization; TV target vessel; TVF target vessel failure; TVR target vessel
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April 10, 2012:1362–70 Primary Endpoint Results of the EVOLVE TrialERGY half dose compared with PROMUS Element,
respectively.
Discussion
In the EVOLVE trial, both dose formulations of the
SYNERGY stent were noninferior compared with the
PROMUS Element stent for the 6-month angiographic
endpoint of in-stent late loss, confirming effective delivery
of everolimus by a unique directional bioabsorbable polymer
system. Six-month clinical event rates were low, and there
were no significant differences among groups. A primary
angiographic endpoint of in-stent late loss was selected for
this study as late loss has been demonstrated to be highly
predictive of clinical revascularization rates (17). The in-
stent late loss recorded in the EVOLVE trial corresponds
well with that reported at 6 months for the durable polymer
Cypher sirolimus-eluting stent (Cordis, Warren, New Jer-
sey) in the RAVEL (A Randomized Comparison of a
Sirolimus-Eluting Stent with a Standard Stent for Coronary
Revascularization) trial (0.01  0.33 mm) (18), and the
durable polymer Xience V EES (Abbott Vascular, Santa
Clara, California) in the SPIRIT FIRST (0.10  0.21 mm)
19) and SPIRIT II (0.11  0.27 mm) (20) trials, and is
umerically less than that reported at 9 months for the
urable polymer Resolute zotarolimus-eluting stent
Medtronic Cardiovascular, Santa Rosa, California) in
he RESOLUTE (A Randomized Comparison of a
otarolimus-Eluting Stent with an Everolimus-eluting
tent for Percutaneous Coronary Intervention) trial (0.22
.27 mm) (21). It is also consistent with that reported in
rst human experiences of bioabsorbable polymer stents,
ncluding the Nobori biolimus-eluting stent (Terumo Cor-
oration, Tokyo, Japan) in the NOBORI I (Randomized
omparison of the Nobori-Biolimus A9-Eluting Coronary
tent with the TAXUS Liberte Paclitaxel-Eluting Coro-
Figure 2 Cumulative Frequency Distribution of In-Stent Late Lo
Cumulative frequency distribution of in-stent late loss by study stent: PROMUS Eleary Stent in Patients with Stenosis in Native Coronary irteries) phase 2 trial (0.11  0.30 mm at 9 months) (22),
he Nevo sirolimus-eluting stent (Cordis Corporation,
ridgewater, New Jersey) in the NEVO RES-I (NEVO
es-Elution I) trial (0.13 0.31 mm at 6 months) (23), and
the Orsiro sirolimus-eluting stent (Biotronik AG, Bulach,
Switzerland) in the BIOFLOW-I (First in Man Experience
with a Drug Eluting Stent in De Novo Coronary Artery
Lesions) trial (0.12 0.19 mm at 4 months) (24). A similar
6-month late loss has also been reported by Serruys et al.
(25) for the bioabsorbable everolimus-eluting vascular scaf-
fold (BVS, Abbott Vascular) in the ABSORB (A Clinical
Evaluation of a Bioabsorbable Everolimus Eluting Coro-
nary Stent System [BVS EECS] in the Treatment of
Patients with de Novo Native Coronary Artery Lesions)
cohort B study (0.19 0.18 mm). Collectively, these results
uggest that the efficacy of the SYNERGY stent is compa-
able to that of established durable polymer as well as
ewer-generation bioabsorbable polymer and bioabsorbable
tent platforms delivering limus-based antiproliferative
rugs.
Although late loss was comparable, it is noteworthy that
everal angiographic outcomes including acute gain, mini-
um lumen diameter, and percent diameter stenosis fa-
ored SYNERGY half dose compared with PROMUS
lement. It is not clear whether these observations are a
onsequence of the difference in baseline reference vessel
iameter between SYNERGY half dose and PROMUS
lement or a play of chance. In either case, the angiographic
utcomes of the EVOLVE study suggest that it may be
ossible to achieve at least comparable efficacy with a lower
ose of everolimus than is used in commercially available
ES. This finding needs to be confirmed in future random-
zed, controlled studies evaluating the low-dose formulation
n a larger patient population.
By demonstrating a significant reduction in revascular-
(blue line), SYNERGY (yellow line), and SYNERGY half dose (green line).ss
mentzation, stent thrombosis, and periprocedural MI compared
0
l
d
e
i
p
m
s
W
s
s
t
t
a
t
S
t
d
fi
l
1368 Meredith et al. JACC Vol. 59, No. 15, 2012
Primary Endpoint Results of the EVOLVE Trial April 10, 2012:1362–70with earlier-generation paclitaxel-eluting stents, durable
polymer EES have become the most widely used drug-
eluting stents worldwide (26,27). The SYNERGY stent is
the only bioabsorbable polymer EES that is currently
undergoing clinical investigation. Besides delivering a po-
tent antirestenotic drug, the SYNERGY stent provides
additional features that may improve clinical outcomes.
First, the thin-strut platinum-chromium stent platform is
designed to improve radiopacity, deliverability, radial
strength, and fracture resistance while reducing recoil,
compared with predicate stainless steel and cobalt-
chromium stent platforms. Second, the ultrathin bioabsorb-
able PLGA polymer delivering everolimus is applied only to
the abluminal surface of the stent, avoiding both drug and
polymer on the luminal surface. The polymer degrades into
carbon dioxide and water within 4 months, leaving only the
biologically inert bare-metal platform behind (11). Elimi-
nation of chronic exposure to the drug and polymer holds
potential to reduce late adverse events and the need for
prolonged DAPT. Although some patient populations have
been shown to benefit from longer DAPT (28), shorter
DAPT may enhance the clinical benefit of drug-eluting
stents in a wide range of patient populations including those
who are at an increased risk for bleeding complications,
patients resistant to DAPT, patients with coexisting re-
quirements for anticoagulation therapy with warfarin, and
patients requiring unplanned invasive procedures. More-
over, in the current era, as cost effectiveness has become an
integral component for evaluation of treatment options, the
possible reduction in DAPT can potentially offer an eco-
nomic benefit. Indeed, ongoing investigations of bioabsorb-
Quantitative Coronary Angiography OutcomesTable 3 Quantitative Coronary Angiography
Angiography Outcomes
PROMU
(n
Post-procedure
MLD, in-stent, mm 2.44 0.36 (2
MLD, in-segment, mm 2.05 0.42 (1
Acute gain, in-stent, mm 1.76 0.38 (1
Acute gain, in-segment, mm 1.38 0.42 (1
Diameter stenosis, in-stent, % 3.77 9.29 (
Diameter stenosis, in-segment, % 19.57 9.26 (1
6 months
MLD, in-stent, mm 2.29 0.50 (2
MLD, in-segment, mm 1.97 0.48 (1
Diameter stenosis, in-stent, % 8.95 14.97 (
Diameter stenosis, in-segment, % 22.02 13.30 (
Late loss, in-stent, mm 0.15 0.34 (
Late loss, in-segment, mm 0.08 0.34 (
Binary restenosis, in-stent, % 3.2 (
Binary restenosis, in-segment, % 5.3 (
Values are mean SD (25th percentile, median, 75th percentile) or %
from the Wilcoxon rank sum test. The Wilcoxon rank sum test was p
Similar results were observed with both tests.
MLD  minimal lumen diameter.able polymeric stents with long-term follow-up have shown tpromising outcomes. In the LEADERS (Limus Eluted
from A Durable versus ERodable Stent coating) trial, the
noninferiority of bioabsorbable polymer biolimus-eluting
stent (BioMatrix Flex, Biosensors, Newport Beach, Califor-
nia) for major adverse cardiac events compared with the
durable polymer sirolimus-eluting stent (Cypher SELECT,
Cordis, Miami Lakes, Florida) observed at 1 year (29), was
maintained to 4 years with a lower risk of definite stent
thrombosis between 1 and 4 years in the biolimus group
(rate ratio: 0.20, 95% confidence interval: 0.06 to 0.67, p 
.004) (30). Additionally, in the post-marketing surveil-
ance CREATE (Multi-Center Registry of EXCEL Bio-
egradable Polymer Drug-Eluting Stents) registry, which
nrolled 2,077 “real-world” patients, the 3-year cumulative
ncidence of stent thrombosis was 1.53% despite 80% of
atients discontinuing thienopyridine therapy within 6
onths after implantation of a bioabsorbable polymer
irolimus-eluting stent (EXCEL, JW Medical System,
eihai, China) (31).
In the EVOLVE trial, the efficacy of the SYNERGY
tent was comparable to that of the PROMUS Element
tent at 6 months, with comparable safety outcomes. Fur-
hermore, no stent thrombosis was reported in any group
hrough 6 months. These preliminary data are encouraging,
nd warrant further investigation in a larger randomized
rial.
tudy limitations. The EVOLVE trial has several impor-
ant limitations. First, the trial was not powered to detect
ifferences in clinical event rates. Second, similar to other
rst human use trials, patients with relatively simple de novo
esions were enrolled, and hence these results may not apply
omes
ment SYNERGY
(n  94)
43, 2.67) 2.51 0.37 (2.21, 2.46, 2.80)
99, 2.33) 2.14 0.41 (1.91, 2.11, 2.41)
70, 2.04) 1.83 0.39 (1.55, 1.82, 2.07)
36, 1.61) 1.46 0.44 (1.17, 1.43, 1.74)
5.17, 11.09) 3.23 9.62 (1.89, 2.18, 10.23)
7.51, 23.12) 18.06 8.46 (11.37, 16.34, 23.36)
30, 2.57) 2.41 0.42 (2.13, 2.38, 2.70)
96, 2.29) 2.06 0.45 (1.75, 2.04, 2.42)
.05, 13.39) 6.59 9.90 (0.57, 5.83, 11.40)
18.90, 25.62) 20.33 10.96 (11.74, 19.00, 25.23)
0.09, 0.26) 0.10 0.25 (0.08, 0.07, 0.24)
0.04, 0.24) 0.07 0.25 (0.06, 0.02, 0.18)
0.0 (0)
2.3 (2)
e p values are from the Student t test; the p values in parentheses are
ed as a post-hoc analysis as the data were not normally distributed.Outc
S Ele
 98)
.15, 2.
.79, 1.
.45, 1.
.12, 1.
4.09,
3.37, 1
.03, 2.
.72, 1.
0.22, 8
14.07,
0.05,
0.11,
3)
5)
(n). Th
erformo more complex patients or lesions. Finally, the EVOLVE
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reduces thrombotic events and the necessity of prolonged
DAPT. A larger study in a broader patient population that
is adequately powered to detect clinical differences and a
separate study comparing long and short DAPT regimens
are planned to elucidate important clinical and cost-
effectiveness outcomes.
Conclusions
In this prospective, randomized, multicenter, first human
use trial, the 2 dose formulations of the SYNERGY stent
were noninferior to the PROMUS Element stent for the
primary angiographic endpoint of in-stent late loss at 6
months. Clinical event rates were low and comparable, with
no stent thrombosis in any group. These results support the
safety and efficacy of the abluminal bioabsorbable polymer
SYNERGY EES for the treatment of patients with de novo
coronary artery disease.
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